Antibodies protect mice from developing respiratory tularemiaJune 28, 2007WHAT: The respiratory form of tularemia, a potentially serious bacterial disease, is a significant public health concern because it is highly infectious, it has a high mortality rate if untreated, and it could be introduced into a population in an intentional act of bioterror. Though much research is focused on developing drugs and vaccines targeted to the bacterium that causes tularemia, Francisella tularensis, little is known about the role that antibodies play in protecting against infection. A research team led by Dennis W. Metzger, Ph.D., at the Albany Medical College in New York has now shown that treating laboratory mice with a serum containing tularemia-specific antibodies protects the mice against F. tularensis, not only if given before exposure to lethal doses of inhalational F. tularensis but also up to 48 hours after exposure. These findings suggest a possible alternative treatment approach to traditional antibiotics. In the absence of a licensed vaccine, such an approach might prove especially useful early on in the case of an intentional act of bioterrorism. The tularemia-specific antibodies may enhance an individual's immune responses to the bacteria after exposure, in essence acting as a surrogate vaccine. Other advantages of this approach over conventional methods of treatment include the fact that it is rapid and specific; it could be used in people with weakened immune systems; and it minimizes the chances of contributing to treatment-resistant bacteria. NIH/National Institute of Allergy and Infectious Diseases |
|||||||||||||||||||||
| Related Tularemia Current Events and Tularemia News Articles Outfoxing pox: Developing a new class of vaccine candidates In the annals of medicine, Edward Jenner's 1796 vaccination of a young boy against smallpox, using fluid from cowpox blisters, remains a landmark case. In a new study, Kathryn Sykes, a researcher at Arizona State University's Biodesign Institute and her colleagues have taken a fresh look at cowpox. Researchers find pathway and enzyme unique to tularemia organism Researchers are closer to developing therapies to combat the deadly tularemia infection, according to a study published this week in the Proceedings of the National Academy of Sciences' online Early Edition. UCLA develops safer, more effective TB vaccine for HIV-positive people UCLA scientists engineered a new tuberculosis (TB) vaccine specifically designed for HIV-positive people that was shown to be safer and more potent than the current TB vaccine in preclinical trials. Researchers uncover molecule that keeps pathogens like salmonella in check Scientists at UT Southwestern Medical Center have found a potential new way to stop the bacteria that cause gastroenteritis, tularemia and severe diarrhea from making people sick. Francisella tularensis: Stopping a biological weapon Scientists hope a vaccine is on the horizon for tularemia, a fatal disease caused by the pathogen Francisella tularensis, an organism of concern as a potential biological warfare agent. Until recently we knew very little about this bacterium. UTSA/UTHSCSA publish results on bio-threat agent Researchers at The University of Texas at San Antonio (UTSA) South Texas Center for Emerging Infectious Diseases and The University of Texas Health Science Center at San Antonio (UTHSCSA) have identified a cell type believed to play a role in controlling the early infectious process against Francisella tularensis, a respiratory pathogen and bioterrorism agent that is the cause of tularemia. Study gives clues about how deadly bacterium gains foothold How a potentially deadly bacterium that could be used as a bioterrorist tool eludes being killed by the human immune system is now better understood. Study gives clues about how deadly bacterium gains foothold How a potentially deadly bacterium that could be used as a bioterrorist tool eludes being killed by the human immune system is now better understood, University of Iowa researchers report in the December issue of the Journal of Leukocyte Biology. New NIAID program aims to model immune responses and key infectious diseases A new program at the National Institute of Allergy and Infectious Diseases (NIAID), one of the National Institutes of Health (NIH), aims to better understand the complex biochemical networks that regulate the interactions between infectious organisms and the human or animal cells they infect. Tiny avalanche photodiodes target bioterrorism agents After the anthrax attacks in the United States in 2001 the threat of a larger and more deadly bioterrorism attack - perhaps from smallpox, plague or tularemia - became very real. But the ability to detect such biological agents and rapidly contain an attack is still being developed. More Tularemia Current Events and Tularemia News Articles |
|||||||||||||||||||||
|
|||||||||||||||||||||
|
|||||||||||||||||||||